Nasal spray shows promise against deadly brain cancer
NCT ID NCT02704858
First seen Jan 05, 2026 · Last updated Jun 20, 2026 · Updated 26 times
Summary
This study tests a nasal spray drug called NEO100 (perillyl alcohol) in people with aggressive brain tumors (grade III or IV gliomas) that have come back or worsened. The trial has two phases: first to find the safest dose, then to see if it helps patients live longer. About 49 participants will take the drug four times daily in 28-day cycles.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA MULTIFORME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Atlantic Health (Overlook Medical Center)
RECRUITINGSummit, New Jersey, 07901, United States
Contact
-
Baylor Scott & White Health
RECRUITINGDallas, Texas, 75061, United States
Contact Email: •••••@•••••
-
Cleveland Clinic
RECRUITINGCleveland, Ohio, 44333, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Georgia Cancer Center (Augusta University)
RECRUITINGAugusta, Georgia, 30912, United States
Contact
Contact Email: •••••@•••••
-
Northwell Health
RECRUITINGNew York, New York, 10016, United States
Contact Email: •••••@•••••
Contact
-
Ochsner Health
RECRUITINGNew Orleans, Louisiana, 70121, United States
Contact
-
Saint John Cancer Institute
RECRUITINGSanta Monica, California, 90404, United States
Contact
-
University of Southern California
RECRUITINGLos Angeles, California, 90033, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Texas Southwestern Medical Center
RECRUITINGDallas, Texas, 75235, United States
Contact
-
University of Washington Medical Center
NOT_YET_RECRUITINGSeattle, Washington, 98105, United States
Contact
-
University of Wisconsin Hospital and Clinic
NOT_YET_RECRUITINGMadison, Wisconsin, 53792, United States
Contact
-
Wake Forest University Health Sciences
RECRUITINGWinston-Salem, North Carolina, 27157, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Perillyl alcohol (NEO100)
What this could lead to
If successful, this could offer a new treatment option for people with aggressive brain tumors that have returned or worsened.
What could go wrong
This is an early-phase trial with only 49 participants, so results may not apply to all patients. The drug is self-administered and may cause side effects or fail to improve survival.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.